Chimerix cell biologist Phiroze Sethna draws samples to help him begin to grow and study new cells in his anti-viral research in 2011. Chimerix’s value has plummeted from $2.5 billion last summer to $180 million last week, forcing Chimerix to shed about a quarter of its workforce – about 40 employees – in a bid to stretch its budget.
Chimerix cell biologist Phiroze Sethna draws samples to help him begin to grow and study new cells in his anti-viral research in 2011. Chimerix’s value has plummeted from $2.5 billion last summer to $180 million last week, forcing Chimerix to shed about a quarter of its workforce – about 40 employees – in a bid to stretch its budget. 2011 News & Observer File Photo - HARRY LYNCH hlynch@newsobserver.com
Chimerix cell biologist Phiroze Sethna draws samples to help him begin to grow and study new cells in his anti-viral research in 2011. Chimerix’s value has plummeted from $2.5 billion last summer to $180 million last week, forcing Chimerix to shed about a quarter of its workforce – about 40 employees – in a bid to stretch its budget. 2011 News & Observer File Photo - HARRY LYNCH hlynch@newsobserver.com

Business

Chimerix pins hopes on smallpox antidote

July 08, 2016 5:13 PM

  Comments  

Videos